clinical trial · NCT05175131
Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
Abbott·phase3·completed·n = 465
Functional Bowel DisorderMebeverine+SimethiconeMebeverineSimethicone
brief summary
The parallel three-group study of efficacy and safety was planned to investigate the reduction in abdominal pain and bloating during treatment with the fixed-dose combination of Mebeverine + Simethicone versus Duspatalin® and Espumisan® as a monotherapy (Protocol No. MESI3001).
started
Nov 27, 2020
primary completion
May 18, 2021
completion
May 18, 2021
last updated
Sep 16, 2025
official title
Multicenter, Randomized, Parallel-group, Open-label, Comparative Clinical Study to Evaluate Efficacy and Safety of Mebeverine+Simethicone Fixed-dose Combination Versus Duspatalin® (Mebeverine) and Versus Espumisan® (Simethicone) in Patients With Functional Bowel Disorders With Abdominal Pain and Excess Gas Formation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol